参考文献 1.Antunes AA.Srougi M,Coelho RF,de Campos Freire G.Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Nat Clin Pract Urol,2007,4:155-160 2.Mittra S,Malhotra S,Naruganahalli KS,Chugh A.Role of peripheral 5-H(1A) receptors in detrusor over activity associated with partial bladder outlet obstruction in female rats.Eur J Pharmacol,2007,561:189-193 3.Dmochowski R.Sand PK.Botulinum toxin A in the overactive bladder:current status and future directions.BJU Int,2007,99:247-262 4.Sen I,Onaran M,Tan MO,Acar C,Camtosun A,Sozen S,Bozkirli I.Evaluation of sexual function in women with overactive bladder syndrome.Urol Int, 2007,78:112-115 5.Son H,Lee SL,Park WH,Park K,Park S,Kang MS,Kim DY,Kim SW,Paick JS.New unstable bladder model in hypercholesterolemia rats.Urology,2007,69:186-190 6.Dmochowski RR,Newman DK.Impact of overactive bladder on women in the United States:results of a national survey.Curr Med Res Opin,2007,23:65-76 7.MacDiarmid S,Rogers A.Male overactive bladder:the role of urodynamics and anticholinergics.Curr Urol Rep,2007,8:66-73 8.Suzuki M,Noguchi Y,Okutsu H,Ohtake A,Sasamata M.Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test.Eur J Pharmacol,2007,557:154-8 9.ChappleC.The contemporary pharmacological management of overactive bladder. BJ0G,2006,113 Suppl2:19-28 10.Milsom I.Overactive bladder:current understanding and future issues.BJOG, 2006,113 Suppl2:2-8 11.Cardozo L.A review of medical management of the overactive bladder syndrome. BJ0G,2006,113:1 12.Lazzeri M,Spinelli M.The challenge of overactive bladder therapy:alternative to antimuscarinic agents.Int Braz J Urol,2006,32:620-630 13.Mukerji G,Waters J,Chessell IP,Bountra C,Agarwal SK,Anand P.Pain during 参考文献 1. Antunes AA, Srougi M, Coelho RF, de Campos Freire G. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Nat Clin Pract Urol, 2007,4:155-160 2. Mittra S, Malhotra S, Naruganahalli KS, Chugh A. Role of peripheral 5-HT(1A) receptors in detrusor over activity associated with partial bladder outlet obstruction in female rats.Eur J Pharmacol, 2007,561:189-193 3. Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions.BJU Int, 2007,99:247-262 4. Sen I, Onaran M, Tan MO, Acar C, Camtosun A, Sozen S, Bozkirli I. Evaluation of sexual function in women with overactive bladder syndrome. Urol Int, 2007,78:112-115 5. Son H, Lee SL, Park WH, Park K, Park S, Kang MS, Kim DY, Kim SW, Paick JS. New unstable bladder model in hypercholesterolemia rats.Urology, 2007,69:186-190 6. Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin, 2007,23:65-76 7. MacDiarmid S, Rogers A. Male overactive bladder: the role of urodynamics and anticholinergics. Curr Urol Rep, 2007,8:66-73 8. Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur J Pharmacol, 2007,557:154-8 9. Chapple C. The contemporary pharmacological management of overactive bladder. BJOG, 2006,113 Suppl 2:19-28 10. Milsom I.Overactive bladder: current understanding and future issues. BJOG, 2006,113 Suppl 2:2-8 11. Cardozo L. A review of medical management of the overactive bladder syndrome. BJOG, 2006,113:1 12. Lazzeri M, Spinelli M. The challenge of overactive bladder therapy: alternative to antimuscarinic agents. Int Braz J Urol, 2006,32:620-630 13. Mukerji G, Waters J, Chessell IP, Bountra C, Agarwal SK, Anand P. Pain during